"I'm delighted to welcome Anne Marie Cook to Phathom. Her experience and broad skills will be highly impactful as we work to build Phathom into a leading GI company in the coming years,” said Steven ...

Biogen Inc. closed 46.93% short of its 52-week high of $238.00, which the company achieved on July 12th.

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve shareholders' best ...

Biogen’s 4 nominations in the Pharma category for its Friedreich’s ataxia work included 3 in the “direct-to-patient ads for ...

Company News Published 06/18/2025, 07:35 AM 0 Biogen initiates phase 3 trial of omaveloxolone for children with FA BIIB -0.66% ...

TORONTO, June 5, 2025 /CNW/ - Biogen Canada Inc. is disappointed by INESSS's recommendation against listing SKYCLARYS™ (omaveloxolone), despite its therapeutic potential for individuals living with ...

Revenue Growth: Biogen's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 6.13%.

A February conference by the drug company Biogen was initially thought to have infected 99 people. By the end of October, it was feared that the number had grown as high as 300,000.

Biogen Inc. (NASDAQ:BIIB) is one of the most undervalued US stocks according to analysts. On June 25, Biogen announced ...

For Capstan, AbbVie will pay up to $2.1 billion in cash, subject to certain customary adjustments. Capstan is backed by ...